Clinical trials
Every registered trial of SS-31 (Elamipretide)
33 studies, 2 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- SS-31 (Elamipretide) has a real but limited body of human research.
- 33 registered studies in total.
- 2 are still enrolling people, so this is active research, not just history.
What kind of research
- 32 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 2,231 people took part in those.
How far along it is
- 5 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 7 have published results in the medical literature that anyone can read.
- The research spans 22 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 33 of 33 trials for SS-31 (Elamipretide).
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Stealth BioTherapeutics Inc.
Barth Syndrome
A Phase IIIb/IV, randomized, double-blind, parallel-group, placebo-controlled, trial to evaluate the efficacy and safety of daily subcutaneous injections of elamipretide in patients with genetically confirmed Barth syndrome
Stealth BioTherapeutics (United States)
Barth Syndrome
Study of Healthy Aging and Physical Function With Elamipretide
David Marcinek
Aging, Healthy
SPIAM-301
Stealth Biotherapeutics Inc.
Dry Age-Related Macular Degeneration (Dry AMD)
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Stealth BioTherapeutics Inc.
Age Related Macular Degeneration (ARMD)
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Stealth BioTherapeutics Inc.
Mitochondrial Myopathies · Mitochondrial Pathology · Mitochondrial DNA Mutation · Mitochondrial Diseases
FRDA Investigator Initiated Study (IIS) With Elamipretide
Children's Hospital of Philadelphia
Friedreich Ataxia
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Stealth BioTherapeutics Inc.
Age-related Macular Degeneration
A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
Stealth BioTherapeutics Inc.
Primary Mitochondrial Myopathy
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
Stealth BioTherapeutics Inc.
Barth Syndrome
Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
Stealth BioTherapeutics Inc.
Primary Mitochondrial Disease
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Stealth BioTherapeutics Inc.
Age-Related Macular Degeneration
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
Stealth BioTherapeutics Inc.
Heart Failure
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
Stealth BioTherapeutics Inc.
Chronic Heart Failure
Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
Stealth BioTherapeutics Inc.
Primary Mitochondrial Disease
Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Stealth BioTherapeutics Inc.
Heart Failure
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy
Stealth BioTherapeutics Inc.
Leber's Hereditary Optic Neuropathy
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
Stealth BioTherapeutics Inc.
Fuchs' Corneal Endothelial Dystrophy (FCED)
A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function
Stealth BioTherapeutics Inc.
Normal and Impaired Renal Function
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure
Stealth BioTherapeutics Inc.
Heart Failure
Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
Stealth BioTherapeutics Inc.
Mitochondrial Myopathy
A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly
Stealth BioTherapeutics Inc.
Skeletal Muscle Mitochondrial Dysfunction in the Elderly
A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration
Stealth BioTherapeutics Inc.
Diabetic Macular Edema · Age-related Macular Degeneration
A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure
Stealth BioTherapeutics Inc.
Congestive Heart Failure
Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days
Stealth BioTherapeutics Inc.
Healthy Volunteers
Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
Stealth BioTherapeutics Inc.
Renal Artery Obstruction · Hypertension, Renovascular · Ischemia Reperfusion Injury
A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)
Stealth BioTherapeutics Inc.
Healthy
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
Stealth BioTherapeutics Inc.
Reperfusion Injury · STEMI
Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia
Stealth BioTherapeutics Inc.
Healthy Volunteers
The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking
Stealth BioTherapeutics Inc.
Healthy Volunteers
Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults
Stealth BioTherapeutics Inc.
Healthy
- NCT04689360Available
An Intermediate Size Expanded Access Protocol of Elamipretide
Stealth BioTherapeutics Inc.
Mitochondrial Diseases · Barth Syndrome
SPIBA-401
Stealth Biotherapeutics Inc.
Barth Syndrome
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when SS-31 (Elamipretide) is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.